Breast Cancer Research and Treatment

, Volume 109, Issue 1, pp 59–65

Fulvestrant (Faslodex™) in advanced breast cancer: clinical experience from a Belgian cooperative study

  • Patrick Neven
  • Robert Paridaens
  • Gino Pelgrims
  • Marc Martens
  • Alain Bols
  • Jean Charles Goeminne
  • Anita Vindevoghel
  • Jan Demol
  • Barbara Stragier
  • Jacques De Greve
  • Christel Fontaine
  • Danielle Van Den Weyngaert
  • Dominique Becquart
  • Marleen Borms
  • Veronique Cocquyt
  • Rudy Van Den Broecke
  • Jean Selleslags
  • Ahmad Awada
  • Luc Dirix
  • Peter Van Dam
  • Marie Agnes Azerad
  • Guy Vandenhoven
  • Marie Rose Christiaens
  • Ignace Vergote
Clinical Trial

DOI: 10.1007/s10549-007-9628-2

Cite this article as:
Neven, P., Paridaens, R., Pelgrims, G. et al. Breast Cancer Res Treat (2008) 109: 59. doi:10.1007/s10549-007-9628-2

Abstract

Fulvestrant (Faslodex™) is a new estrogen receptor (ER) antagonist with no agonist effects that is licensed for the treatment of postmenopausal women with hormone-sensitive advanced breast cancer (ABC) who have progressed/recurred on prior antiestrogen therapy. The Faslodex™ Compassionate Use Program (CUP) provides expanded access to fulvestrant in countries where it is not yet available for patients who are not eligible to enter clinical trials. This analysis pools data from 402 patients who received fulvestrant as part of the CUP in Belgium, predominantly as 3rd- to 5th-line endocrine therapy for ABC. Two patients experienced partial responses and 118 experienced stable disease lasting ≥6 months, resulting in an overall clinical benefit rate of 29.9%. Fulvestrant was active in patients with multiple sites of metastases, visceral metastases, human epidermal growth factor receptor 2-positive disease and after heavy endocrine pre-treatment. Fulvestrant was well tolerated, with only six patients (1.5%) discontinuing treatment following adverse events. These data support the findings of previous CUP analyses and Phase II and III trials, suggesting that fulvestrant is a valuable addition to the treatment sequence for postmenopausal women with ABC who have progressed/recurred on prior endocrine therapy.

Keywords

Advanced or metastatic breast cancer Compassionate use Endocrine Fulvestrant Postmenopausal 

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Patrick Neven
    • 1
  • Robert Paridaens
    • 1
  • Gino Pelgrims
    • 2
  • Marc Martens
    • 2
  • Alain Bols
    • 3
  • Jean Charles Goeminne
    • 4
  • Anita Vindevoghel
    • 4
  • Jan Demol
    • 5
  • Barbara Stragier
    • 5
  • Jacques De Greve
    • 6
  • Christel Fontaine
    • 6
  • Danielle Van Den Weyngaert
    • 7
  • Dominique Becquart
    • 7
  • Marleen Borms
    • 8
  • Veronique Cocquyt
    • 9
  • Rudy Van Den Broecke
    • 9
  • Jean Selleslags
    • 10
  • Ahmad Awada
    • 10
  • Luc Dirix
    • 11
  • Peter Van Dam
    • 11
  • Marie Agnes Azerad
    • 12
  • Guy Vandenhoven
    • 12
  • Marie Rose Christiaens
    • 1
  • Ignace Vergote
    • 1
  1. 1.Multidisciplinary Breast Centre & Gynaecological OncologyUZ KULeuvenLeuvenBelgium
  2. 2.St. ElisabethTurnhoutBelgium
  3. 3.AZ St. JanBruggeBelgium
  4. 4.Clinique St. ElisabethNamurBelgium
  5. 5.Heilig HartkliniekRoeselareBelgium
  6. 6.AZ VUBBrusselsBelgium
  7. 7.AZ MiddelheimAntwerpenBelgium
  8. 8.AZ GroeningeKortrijkBelgium
  9. 9.UZ GentGentBelgium
  10. 10.Institut BordetBrusselsBelgium
  11. 11.AZ St. AugustinusAntwerpenBelgium
  12. 12.AstraZenecaBrusselsBelgium

Personalised recommendations